Morphotek Achieves LEED® Certification For New Pilot Plant

          Morphotek Achieves LEED® Certification For New Pilot Plant

Earns V2.2 Gold Certification for New Construction

PR Newswire

EXTON, Pa., July 3, 2013

EXTON, Pa., July 3, 2013 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of
Eisai Inc., announced today that it has achieved LEED® certification for its
new 60,000-square-foot pilot plant facility located in Exton, Pennsylvania.

LEED (Leadership in Energy and Environmental Design) is a voluntary,
consensus-based, market-driven program developed by the U.S. Green Building
Council that provides third-party verification of green buildings. The LEED
Green Building Rating System assesses the way buildings are designed,
constructed and operated. For a commercial building to earn LEED
certification, a project must satisfy all LEED prerequisites and earn a
minimum number of points on the LEED rating system, which consists of the
following categories: Sustainable Sites, Water Efficiency, Energy and
Atmosphere, Materials and Resources, Indoor Environmental Quality, Innovation
and Design Process, and Regional Priority.

"Morphotek should be extremely proud of this achievement. Their passion and
commitment to sustainability helps to establish a new standard for their
industry and demonstrates remarkable green building leadership," said Brian
Falcon, AIA, LEED AP BD+C, of Arcus Design Group – Architects, Inc. Falcon
served as the LEED Project Architect for the pilot plant.

As part of Morphotek's commitment to environmental stewardship, the project
team for the pilot plant made LEED certification a high priority in the
programming process. The company also implemented Integrated Project Delivery
and Building Information Modeling to prioritize sustainable choices early in
the schematic design and ensure cost efficiency.

The project included the clean-up of a previously developed brownfield site,
and utilized much of the infrastructure of the old buildings in the new plant.
As a result, ninety-two percent of construction waste was diverted from
landfills. In addition, all asphalt and masonry from existing demolished
buildings were crushed and reused on site.

The building envelope incorporates prefabricated metal panels, advanced
insulation, and architectural elements to control solar gain. Zoned lighting
with occupancy sensors, solar tubes and strategic placement of open and
private offices maximize daylight exposure. Increased ventilation and
low-emitting materials improve employee comfort.

The facility was designed to be 33.2 percent more energy efficient than a
standard code compliant pharmaceutical building. An 84 kW PV system is
expected to generate 100,000 kW per year.

The plant is also designed to be water efficient, utilizing water-efficient
landscaping and naturalized bio-retention areas to treat storm water. In all,
it is expected to be 30 percent more efficient than base case, saving
approximately two million gallons annually.

About Morphotek, Inc.

Morphotek^®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company
specializing in the development of protein and antibody products through the
use of a novel and proprietary gene evolution technology.The technology has
been successfully applied to a broad variety of cell lines and organisms to
yield genetically diverse offspring that are suitable for pharmaceutical
product development in the areas of antibody therapeutics, protein
therapeutics, product manufacturing, drug target discovery, and improved
output traits for commercial applications.The company is currently focusing
its platform on the development and manufacturing of therapeutic antibodies
for the treatment of cancer, inflammation and infectious disease.For more
information, please visit www.morphotek.com. 

About Eisai Inc.

At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co.,
Ltd., our passionate commitment to patient care is the driving force behind
our efforts to help address unmet medical needs. We are a fully integrated
pharmaceutical business with discovery, clinical, manufacturing and marketing
capabilities. Our key areas of commercial focus include oncology and specialty
care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more
about Eisai Inc., please visit us at www.eisai.com/US. 

Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai's
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based
programs.

Contacts: Media and Investor      Media Inquiries       Investor Inquiries
           Inquiries
           Rod Dausch             Lynn Kenney           Alex Scott
           Morphotek, Inc.        Eisai Inc.            Eisai Inc.
           610-423-6111           201-746-2294          201-746-2177
           Dausch@morphotek.com   lynn_kenney@eisai.com alex_scott@eisai.com



SOURCE Morphotek Inc.

Website: http://www.morphotek.com
 
Press spacebar to pause and continue. Press esc to stop.